HuidaGene Secures US Patent for High-Efficiency Cas12Max DNA Editing System
HuidaGene Therapeutics, a China-based biotechnology company, has announced the receipt of patent protection from the...
Jiangsu Hengrui’s SHR0302 Secures Clinical Trial Approval for GVHD Treatment
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading China-based pharmaceutical company, has announced the receipt of...
Sanofi’s VaxigripTetra Expands Influenza Vaccine Access to All Ages in China
French pharmaceutical company Sanofi (NASDAQ: SNY) has announced that its tetravalent influenza virus split vaccine,...
AstraZeneca’s Nirsevimab on Track for Priority Review for RSV Prevention in Infants
The Center for Drug Evaluation (CDE) website in China indicates that AstraZeneca’s (AZ, NASDAQ: AZN)...
Antengene Submits Market Approval Filing for Xpovio in Indonesia for Multiple Myeloma and Lymphoma
Antengene Corp., Ltd (HKG: 6996) has announced a market approval filing in Indonesia for its...
TYK Medicines Receives CDE Approval for CDK7 Inhibitor TY-2699a Clinical Study
Shanghai-based TYK Medicines has announced that it has received approval from the Center for Drug...
Transcenta Holdings’ TST002 Shows Positive Phase I Results for Bone Density in China
China-based biotech Transcenta Holdings Ltd (HKG: 6628) has announced encouraging Phase I clinical study results...
BeiGene’s Tislelizumab Secures First Approvals Outside China Mainland in Macau
BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor,...
Yizun Biomedicine’s CNK-UT Cell Therapy Initiates Patient Enrollment for Solid Tumor Trial
Hangzhou-based cell therapy specialist Yizun Biomedicine Co., Ltd has announced the completion of first patient...
Zelgen Biopharmaceuticals’ Jacktinib Studies Selected for EHA Annual Meeting
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that the results of three clinical...
Zelgen Biopharmaceuticals’ ZG0895 Receives FDA Approval for Clinical Trials in Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...
Coherent Biopharma Secures $100 Million in Series B and B+ Financings for Clinical Pipeline
Coherent Biopharma Ltd, a specialist in bispecific-ligand drug conjugates (Bi-XDC) headquartered in Suzhou, has declared...
Philips Agrees to $62 Million Settlement with SEC Over China Marketing Practices
The US Securities and Exchange Commission (SEC) has announced that Dutch device company Philips (BVMF:...
Drug Farm Secures $27 Million in Series C Financing to Advance HBV Treatments
Drug Farm, a Sino-US biotech company specializing in hepatitis B virus (HBV) treatments, oncology, and...
Peijia Medical Achieves Milestone with First Commercial Implants of Trilogy TAVR System in Hong Kong
Peijia Medical Limited (HKG: 9996), a leading China-based medical device company, has announced the successful...
BiOneCure Therapeutics and Nanjing Leads Biolabs Collaborate on Innovative ADCs for Solid Tumors
US-based biotech company BiOneCure Therapeutics Inc. has entered into a strategic collaboration with China-based Nanjing...
Lynk Pharmaceuticals’ LNK01001 Demonstrates Efficacy in Phase II Rheumatoid Arthritis Study
China-based Lynk Pharmaceuticals Co., Ltd announced positive results from the Phase II clinical study of...
Skyline Therapeutics Initiates Clinical Study with First Patient Dosing of SKG0106 for wAMD
Skyline Therapeutics has reached a significant milestone with the completion of the first patient dosing...
Gracell Biotechnologies Initiates Trial for GC012F in Refractory SLE with Dual-Target FasTCAR Therapy
Gracell Biotechnologies Inc., (Nasdaq: GRCL), a China-based biopharmaceutical company, has announced the start of an...
Aligos Therapeutics Partners with Amoytop Biotech for Oligonucleotide Compound R&D
Liver and viral disease specialist Aligos Therapeutics (NASDAQ: ALGS) announced last week a significant partnership...